Introduction
We are doctors looking after patients with blood disorders and scientists studying blood conditions in the lab. Our aim is to deliver the best expert and compassionate care for patients with blood diseases and patients who need blood cell transfusions. We want to reduce the burden of disease now and in the future, through our research, services, education, outreach and advocacy.
Our group includes international, scientific and clinical leaders. We draw on our combined expertise to carry out research and develop new services. Through our work we aim to:
- Improve the cost-effectiveness of cancer therapies and the outcomes of treatment – by developing new single cell approaches which tailor treatments to individuals. Find out more
- Improve the management of common and rare anaemias – by studying the role of iron and inflammation in anaemic patients, especially those who are elderly, and by developing a new national NHS service for patients with rare inherited red cell disorders. Find out more
- Improve the outcomes of blood cell and blood component transfusions – by using advanced e-tools and carrying out clinical trials to find out what approaches work best. Find out more
- Involve patients and carers in the key steps of our research projects. Find out more
Related websites
Oxford Centre for Haematology website: rdm.ox.ac.uk/och
RDM – HaemBio Biobank pages:
rdm.ox.ac.uk/about/our-clinical-facilities-and-mrc-units/och/haembio
NSSG website: nssg.oxford-haematology.org.uk
Introductory Talk by Haematology and Stem Cells Theme Lead Professor Paresh Vyas
Dr Susie Shapiro discusses research into thrombosis and COVID-19
In this webinar hosted by Thrombosis UK, BRC Haematology and Stem Cells theme researcher Dr Susie Shapiro speaks about her research on thrombosis in relation to COVID-19.
Follow the Oxford Centre for Haematology on Twitter
A limited number of places have been made available at short notice for the @OxfordHaem Annual Meeting Mon 28 June. Open to staff @UniofOxford and @OUHospitals, please make sure to register before 5pm Fri 25 June 👉https://t.co/nhV9me9fee
📢Full schedule published for @OxfordHaem Annual Meeting 28 June, 08:45-17:45👉https://t.co/pHqZ47pJcO
Plenary Prof Andrew Pollard @OxfordVacGroup discusses #COVID19 #vaccines & #thrombosis risk
@MRC_WIMM @MRC_MHU @RDMOxford @OxHealthBRC @OxfordMedSci @UniofOxford #haematology
@OxfordBRC @MRC_WIMM @oxford_blood @OxfordMedSci @OxfordHaem @BloodCancer_Res @CureLeukaemia @NIHRCRN_tvsm @OUHospitals @NIHRresearch @beth_psaila Great thread from lead researcher @beth_psaila explaining this work https://t.co/eKrTRwb6mz
Researchers @MRC_WIMM have found that #antibody response to first doses of COVID-19 vaccine in people with #myeloid blood cancers are not as strong as in the general population https://t.co/hqir9CG9zf @RDMOxford
Flexible funding for all training/education activities (conferences, courses, workshops, team meetings etc…) for anyone working in Haematology in Oxford ⬇️ please apply by July 16th! @OUHospitals @MRC_WIMM @RDMOxford https://t.co/8AHf70AJcQ
This looks like a great day, thank you @graham74GC @OxfordHaem @oxford_blood! https://t.co/MLG9n3hPqk
📢Full schedule published for @OxfordHaem Annual Meeting 28 June, 08:45-17:45👉https://t.co/pHqZ47pJcO
Plenary Prof Andrew Pollard @OxfordVacGroup discusses #COVID19 #vaccines & #thrombosis risk
@MRC_WIMM @MRC_MHU @RDMOxford @OxHealthBRC @OxfordMedSci @UniofOxford #haematology